Serum Interleukin 6 in Chronic Obstructive Pulmonary Disease

Not Applicable

Completed

• Conditions: Chronic Obstr Lung Disease
• Interventions: Diagnostic Test: interleukin 6

• Registration Number: NCT05214508
• Lead Sponsor: Beni-Suef University

Brief Summary

The aim of this study is to estimate level of IL 6 in COPD patients and its relation to COPD severity and acute exacerbation.

Detailed Description

1. A detailed clinical history was be carried out for every patient. In the clinical history, duration of COPD with a history of exacerbation and treatment will be elicited. History of the presence of risk factors such as smoking, exposure to fumes (biomass), and the presence of any other chronic disease were be inquired.

2. Thereafter, the detailed physical examination also had been carried out.

3. Pulmonary function test was performed by master screen NO : 781040 (care fusion) Measurements were obtained for FVC,FEV1,Ratio between them, PEF,FEF25%,FEF50% ,and FEF75% (The readings for FEV1 and Ratio were the ones included in the statistical analysis as indices for obstructive pattern of respiration).

4. Labs including Complete blood count, urea, and serum creatinine ,ESR was done for all patients

5. Exercise capacity by six minutes' walk test.

6. Dyspnea score by MMRC score.

7. Health state assessment by CAT score

3- 8- Determination of IL 6 serum levels. by sandwich enzyme-linked immunosorbent assay (ELISA). The detection range (0.2 ng/L- 8ng/L)

Study Timeline

• Study Start: 2020-03-01
• Primary Completion: 2020-11-01
• Study Completion: 2020-11-30
• Status Verified: 2022-01
• Study First Submitted: 2022-01-14
• Study First Submitted QC: 2022-01-27
• Last Update Submitted: 2022-01-27
• Study First Posted: 2022-01-28
• Last Update Posted: 2022-01-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

1. All patients aged >40 years and <80 years, of both gender
2. Diagnosed to have COPD according to GOLD 2019 by spirometry
3. Given the consent for participation in the study

Exclusion Criteria

1- Any patient with systemic inflammation as

1. Bronchial asthma,
2. rheumatoid arthritis.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
COPD patient	interleukin 6	COPD patients diagnosed based on spirometry, PFT and history

Primary Outcome Measures

Name	Time	Method
measure level of IL-6	9 monthes	using ELISA

Trial Locations

Locations (1)

Beni Suef university; 🇪🇬 Cairo, Egypt